H.C. Wainwright upgraded Rapt Therapeutics (RAPT) to Buy from Neutral with a $10 price target after Rapt and a subsidiary of Jiangxi Jemincare Group, a leading pharmaceutical company in China, announced that they have entered into an exclusive license agreement for JYB1904, or RPT904, a clinical-stage, half-life extended anti-immunoglobulin E monoclonal antibody. Rapt plans to pursue development of RPT904 initially in food allergy, which is a market that represents “a large and lucrative niche,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT:
- Rapt Therapeutics price target raised to $6 from $4 at Wells Fargo
- RAPT Therapeutics Partners with Jemincare and Secures Funding
- RAPT Therapeutics prices 100M shares at 85c in private placement
- Rapt Therapeutics, Jemincare enter exclusive license agreement for JBY1904
- RAPT Therapeutics Reprices Underwater Employee Stock Options
Questions or Comments about the article? Write to editor@tipranks.com